دورية أكاديمية
أعرض في EDS

Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease.

التفاصيل البيبلوغرافية
العنوان: Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease.
المؤلفون: Reyes E; National Heart and Lung Institute, Imperial College London, London, England. e.reyes@rbht.nhs.uk, Loong CY, Wechalekar K, Latus K, Anagnostopoulos C, Underwood SR
المصدر: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology [J Nucl Cardiol] 2007 Nov-Dec; Vol. 14 (6), pp. 827-34. Date of Electronic Publication: 2007 Oct 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc. on behalf of American Society of Nuclear Cardiology Country of Publication: United States NLM ID: 9423534 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6551 (Electronic) Linking ISSN: 10713581 NLM ISO Abbreviation: J Nucl Cardiol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2024- : New York : Elsevier Inc. on behalf of American Society of Nuclear Cardiology
Original Publication: St. Louis, MO : Mosby-Year Book, Inc., c1994-
مواضيع طبية MeSH: Adenosine/*adverse effects , Asthma/*complications , Bronchial Diseases/*chemically induced , Coronary Artery Disease/*complications , Coronary Artery Disease/*diagnostic imaging , Pulmonary Disease, Chronic Obstructive/*complications, Aged ; Asthma/diagnostic imaging ; Bronchial Diseases/diagnostic imaging ; Case-Control Studies ; Constriction, Pathologic/chemically induced ; Constriction, Pathologic/diagnostic imaging ; Dose-Response Relationship, Drug ; Drug Tolerance ; Exercise Test/adverse effects ; Female ; Humans ; Male ; Pulmonary Disease, Chronic Obstructive/diagnostic imaging ; Radionuclide Imaging ; Vasodilator Agents/adverse effects
مستخلص: Background: Adenosine may cause bronchoconstriction in subjects with asthma or chronic obstructive pulmonary disease (COPD). Recent evidence suggests that this effect may be dependent on the severity of disease. This study investigates the tolerability of adenosine stress in patients with mild asthma or COPD undergoing myocardial perfusion scintigraphy.
Methods and Results: In this case-control study patients with known or suspected mild asthma or COPD were pretreated with an inhaled beta(2)-adrenergic agonist and adenosine titrated up to the maximal dose of 140 microg x kg(-1) x min(-1) over a period of 6 minutes. The occurrence of side effects and test tolerability were compared between the airway disease group and 72 control subjects. Of 1261 patients, 124 had known or suspected airway disease; of these, 72 (58%) were suitable for adenosine stress. The proportion of tests completed as per protocol in the asthma/COPD group was similar to that of control subjects (93% vs 100%, P = .06). Dyspnea (n = 38 [53%] in asthma/COPD group vs n = 25 [35%] in control group, P = .03) and chest pain (n = 14 [19%] in asthma/COPD group vs n = 16 [22%] in control group, P = .7) were the most common side effects, and these were mostly mild and well tolerated. Bronchospasm occurred in 5 patients with asthma/COPD but reverted shortly after discontinuation of the adenosine infusion. Aminophylline was not required in any case.
Conclusions: A stepwise 6-minute adenosine infusion with prophylactic beta(2)-adrenergic agonist is safe and well tolerated in patients with mild asthma or COPD.
References: Eur Respir J. 2003 Mar;21(3):473-7. (PMID: 12662004)
J Nucl Cardiol. 2006 Nov;13(6):e80-90. (PMID: 17174798)
Heart. 2004 Aug;90 Suppl 5:v2-9. (PMID: 15254003)
Br J Clin Pharmacol. 1983 Feb;15(2):161-5. (PMID: 6303374)
J Immunol. 2003 Jul 1;171(1):338-45. (PMID: 12817016)
Chest. 1988 Feb;93(2):280-4. (PMID: 3276453)
J Am Coll Cardiol. 2000 Dec;36(7):2017-27. (PMID: 11127435)
J Pharmacol Exp Ther. 2003 Oct;307(1):182-9. (PMID: 12954805)
Clin Sci (Lond). 1988 Oct;75(4):429-36. (PMID: 2461826)
J Am Coll Cardiol. 2005 Dec 6;46(11):2069-75. (PMID: 16325044)
Am J Respir Cell Mol Biol. 2004 Jan;30(1):118-25. (PMID: 12855406)
J Immunol. 2004 Jun 15;172(12):7726-33. (PMID: 15187156)
Pharmacol Rev. 2001 Dec;53(4):527-52. (PMID: 11734617)
J Am Coll Cardiol. 1994 Feb;23(2):384-9. (PMID: 8294691)
Heart. 2004 Jan;90 Suppl 1:i1-10. (PMID: 14676223)
J Am Coll Cardiol. 1995 May;25(6):1300-9. (PMID: 7722125)
Am J Cardiol. 2006 Aug 15;98(4):541-3. (PMID: 16893714)
Mayo Clin Proc. 1999 Apr;74(4):339-46. (PMID: 10221461)
J Allergy Clin Immunol. 2004 Oct;114(4):737-46. (PMID: 15480309)
Chest. 2005 Oct;128(4):2640-6. (PMID: 16236937)
Clin Exp Allergy. 2003 Mar;33(3):287-94. (PMID: 12614440)
Am J Respir Crit Care Med. 2001 Jun;163(7):1546-50. (PMID: 11401871)
Chest. 2005 Oct;128(4):1905-9. (PMID: 16236834)
Am Heart J. 2001 Jul;142(1):142-5. (PMID: 11431670)
J Pharmacol Exp Ther. 2001 Jul;298(1):209-18. (PMID: 11408544)
Circulation. 2002 Jan 29;105(4):539-42. (PMID: 11815441)
المشرفين على المادة: 0 (Vasodilator Agents)
K72T3FS567 (Adenosine)
تواريخ الأحداث: Date Created: 20071121 Date Completed: 20080122 Latest Revision: 20211020
رمز التحديث: 20231215
DOI: 10.1016/j.nuclcard.2007.07.013
PMID: 18022109
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-6551
DOI:10.1016/j.nuclcard.2007.07.013